Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CASSAVA SCIENCES, INC.

(SAVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

(SAVA) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel Regarding Leading Cassava Sciences Class Action Lawsuit

09/25/2021 | 11:15am EDT

SAN DIEGO, Sept. 25, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that purchasers of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, have until October 26, 2021, to file a lead plaintiff motion.

[click here to join this action]

According to the filed complaint: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and lacked a reasonable basis.

A lead plaintiff will act on behalf of all other class members in directing the Casava class-action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the class-action lawsuit.  An investor's ability to share any potential future recovery of the Casava class action lawsuit is not dependent upon serving as lead plaintiff.

If you suffered a substantial loss and are interested in learning more about being a lead plaintiff, please contact Jim Baker (jimb@johnsonfistel.com) by email or phone at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com

Cision
View original content:https://www.prnewswire.com/news-releases/sava-deadline-did-you-suffer-a-substantial-loss-contact-johnson-fistel-regarding-leading-cassava-sciences-class-action-lawsuit-301385092.html

SOURCE Johnson Fistel, LLP


© PRNewswire 2021
All news about CASSAVA SCIENCES, INC.
10/16(SAVA) DEADLINE : Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading ..
PR
10/15SHAREHOLDER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their Investmen..
PR
10/13CASSAVA SCIENCES : SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securiti..
PR
10/10IMPORTANT DEADLINE REMINDER : Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences,..
PR
10/09CASSAVA SCIENCES : ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Cassava Science..
BU
10/07SHAREHOLDER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their Investmen..
PR
10/07CASSAVA SCIENCES : Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Pa..
AQ
10/06CASSAVA SCIENCES : Starts Initial Phase 3 Study on Potential Alzheimer's Disease Treatment..
MT
10/06CASSAVA SCIENCES : Starts Initial Phase 3 Study on Potential Alzheimer's Disease Treatment
MT
10/06CASSAVA SCIENCES : Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Pa..
GL
More news
Analyst Recommendations on CASSAVA SCIENCES, INC.
More recommendations